微信公众号
证券之星APP
| 报告期 | 净资产收益率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | -3.73% | -148.89% | -18.79% | 45/52 | 3.55% | 澳洋健康 | 34.16% | 行业排名> |
| 2024-06-30 | -3.14% | -147.29% | -90.3% | 46/52 | 2.24% | 澳洋健康 | 30.56% | 行业排名> |
| 2024-03-31 | -1.65% | -133.47% | -138.55% | 44/52 | 1.22% | 澳洋健康 | 28.14% | 行业排名> |
| 2023-12-31 | 4.28% | -89.24% | -43.91% | 27/52 | 3.83% | 澳洋健康 | 39.54% | 行业排名> |
| 2023-09-30 | 7.63% | -77.11% | 14.91% | 17/52 | 6.78% | 澳洋健康 | 61.84% | 行业排名> |
| 2023-06-30 | 6.64% | -75.14% | 34.69% | 14/52 | 1.93% | 澳洋健康 | 48.34% | 行业排名> |
| 2023-03-31 | 4.93% | -46.06% | -87.6% | 6/52 | 2.55% | 澳洋健康 | 58.19% | 行业排名> |
| 2022-12-31 | 39.77% | 191.57% | 19.32% | 1/52 | -0.52% | *ST宜康 | 75.53% | 行业排名> |
| 2022-09-30 | 33.33% | 214.14% | 24.78% | 4/52 | 11.21% | 博腾股份 | 39.77% | 行业排名> |
| 2022-06-30 | 26.71% | 349.66% | 192.23% | 3/52 | 5.46% | 睿智医药 | 41.16% | 行业排名> |
| 2022-03-31 | 9.14% | 255.64% | -32.99% | 5/52 | 3.09% | 澳洋健康 | 51.68% | 行业排名> |
| 2021-12-31 | 13.64% | 52.23% | 28.56% | 20/52 | -6.4% | 澳洋健康 | 40.93% | 行业排名> |
| 2021-09-30 | 10.61% | 40.34% | 78.62% | 20/52 | 2.38% | 金域医学 | 43.58% | 行业排名> |
| 2021-06-30 | 5.94% | 55.91% | 131.13% | 23/52 | 2.32% | 金域医学 | 35.41% | 行业排名> |
| 2021-03-31 | 2.57% | 64.74% | -71.32% | 18/52 | 1.85% | 阳光诺和 | 26.2% | 行业排名> |
| 2020-12-31 | 8.96% | 64.1% | 18.52% | 32/52 | 10.94% | 金域医学 | 13.23% | 行业排名> |
| 2020-09-30 | 7.56% | 63.64% | 98.43% | 17/52 | 7.83% | 万邦医药 | 52.05% | 行业排名> |
| 2020-06-30 | 3.81% | 91.46% | 144.23% | 20/52 | 2.51% | 华大基因 | 48.52% | 行业排名> |
| 2020-03-31 | 1.56% | 178.57% | -71.43% | 11/52 | -0.22% | 华大基因 | 31.24% | 行业排名> |
| 2019-12-31 | 5.46% | 62.99% | 18.18% | 34/52 | 64.11% | 阳光诺和 | 13.99% | 行业排名> |
| 2019-09-30 | 4.62% | -9.77% | 132.16% | 20/52 | 10.46% | 南华生物 | 2848.07% | 行业排名> |
| 2019-06-30 | 1.99% | 55.47% | 255.36% | 23/52 | 5.56% | 南华生物 | 98.98% | 行业排名> |
| 2019-03-31 | 0.56% | -64.78% | -83.28% | 22/52 | 3.44% | 南华生物 | 82.46% | 行业排名> |
| 2018-12-31 | 3.35% | -50.74% | -34.57% | 34/52 | -0.5% | 南华生物 | 48.41% | 行业排名> |
| 2018-09-30 | 5.12% | -5.88% | 300% | 17/52 | 2.84% | 万邦医药 | 106.72% | 行业排名> |
| 2018-06-30 | 1.28% | -71.11% | -19.5% | 27/52 | 1.7% | 国际医学 | 46.66% | 行业排名> |
| 2018-03-31 | 1.59% | -63.02% | -76.62% | 12/52 | 0.49% | 普蕊斯 | 22.99% | 行业排名> |
| 2017-12-31 | 6.8% | -53.14% | 25% | 23/52 | 2.03% | 通策医疗 | 6.02% | 行业排名> |
| 2017-09-30 | 5.44% | -47.49% | 22.8% | 17/52 | 8.61% | 普蕊斯 | 58.68% | 行业排名> |
| 2017-06-30 | 4.43% | -46.43% | 3.02% | 14/52 | 58.64% | 爱尔眼科 | 20.87% | 行业排名> |
| 2017-03-31 | 4.3% | 7.77% | -70.37% | 5/52 | -5.59% | 南华生物 | 1666.98% | 行业排名> |
| 2016-12-31 | 14.51% | 24.34% | 40.06% | 14/52 | 19.64% | 爱尔眼科 | 5.19% | 行业排名> |
| 2016-09-30 | 10.36% | 13.97% | 25.27% | 6/52 | 5.93% | 南华生物 | 383.03% | 行业排名> |
| 2016-06-30 | 8.27% | 26.65% | 107.27% | 8/52 | 3.33% | *ST宜康 | 36.84% | 行业排名> |
| 2016-03-31 | 3.99% | 6.12% | -65.81% | 4/52 | 1.51% | 药石科技 | 24.53% | 行业排名> |
| 2015-12-31 | 11.67% | -29.49% | 28.38% | 13/52 | 22.23% | 南华生物 | 55.01% | 行业排名> |
| 2015-09-30 | 9.09% | -2.15% | 39.2% | 8/52 | 5.27% | *ST宜康 | 36.74% | 行业排名> |
| 2015-06-30 | 6.53% | 7.4% | 73.67% | 5/52 | -30.81% | 南华生物 | 24.73% | 行业排名> |
| 2015-03-31 | 3.76% | -42.77% | -77.28% | 6/52 | -5.77% | 南华生物 | 400.84% | 行业排名> |
| 2014-12-31 | 16.55% | -34.94% | 78.15% | 10/52 | -13% | 金域医学 | 22.92% | 行业排名> |
| 2014-09-30 | 9.29% | 2% | 52.8% | 9/52 | -106.33% | 迪安诊断 | 11.5% | 行业排名> |
| 2014-06-30 | 6.08% | -60.44% | -7.46% | 8/52 | -89.54% | 退市海医 | 6.75% | 行业排名> |
| 2014-03-31 | 6.57% | 2% | -74.17% | 2/52 | -7.99% | 国际医学 | 5.94% | 行业排名> |